Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;

 @FierceBiotech: Biotech's Biggest Spenders 2010. Report | Follow @FierceBiotech

 @JohnCFierce: Proving yet again how hot antibody tech is, Boehringer agrees to $1.7B (provided all the stars align) pact with f-star. Article | Follow @JohnCFierce

> The UK's Xention closed an £8 million series D financing to fund the clinical development of its experimental therapies for atrial fibrillation. The financing was led by new investor Seroba-Kernel Life Sciences Ltd and included existing investors Forbion Capital Partners, Crédit Agricole Private Equity, MVM and BTG International. Xention secializes in the discovery and development of ion channel-modulating drugs. Xention release

Special Report: Big Pharma's Top 5 Emerging Market Deals. Report

> Maxygen announced plans to distribute all the shares it owns of Codexis along with $30 million in cash. Maxygen formed Codexis in January 2002 as a wholly owned subsidiary to operate its former chemicals business, and on April 27, 2010, Codexis completed an initial public offering of its common stock. Maxygen release

> BioCancell Therapeutics says it raised $5.1 million from a public offering. BioCancell release

Special Report: Pharma's Top 10 Blockbuster Drugs. Article

> India's Claris Lifesciences has received regulatory approval for an IPO. The Carlyle Group holds a 13.89% stake in Claris. Story

Special Report: Top 10 Generic Drug Companies 2010. Report

And Finally... The big insurer UnitedHealth says that an epidemic of diabetes could cost the U.S. $3.4 trillion over the next 10 years, unless we start to bend the growth rate. Report

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.